

## **ASX ANNOUNCEMENT**

30 September 2009

### **Cytopia achieves grant of further patent for JAK2 program**

Cytopia Ltd (ASX: CYT) announced today that it has further extended its patent protection over the validated JAK2 clinical target with the grant of a further patent in the United States of America.

Cytopia holds the exclusive licence to a family of patents for the drug targets JAK1 and JAK2. The issuance of US patent number 7593820 now augments this coverage by providing protection for the claimed methods of selecting or designing a compound which interacts with JAK2.

Cytopia has developed a library of novel small-molecule JAK2 inhibitors, with the most advanced compound CYT387 having recently been given clearance by the US Food and Drug Administration to enter clinical trials. A Phase I/II clinical trial in patients with myelofibrosis is expected to commence in the United States shortly.

### **Appointment and Resignation of Company Secretary**

Cytopia also announced today the appointment of Mr Ashley Arnott as Chief Financial Officer and Company Secretary with immediate effect. Mr Arnott has held a number of senior finance roles with private and public companies and is an experienced Company Secretary. He holds a Bachelor of Business (Accounting) and is a Graduate Member of Australian Institute of Company Directors.

The appointment follows the resignation of Mr Gavan Flower as Chief Financial Officer and Company Secretary. The CEO of Cytopia, Mr Andrew Macdonald, thanked Mr Flower for his contribution since joining the company in October 2007 and wished him well in his future endeavours.

### **About Cytopia**

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and California, USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialled in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise with CYT387, a novel oral JAK1/JAK2 inhibitor for the treatment of myeloproliferative disorders, to enter a Phase I/II clinical study in 2009.

For more information please contact:

Mr Andrew Macdonald  
Chief Executive Officer  
T: +61 3 9208 4232  
E: [andrew.macdonald@cytopia.com.au](mailto:andrew.macdonald@cytopia.com.au)

or visit our website at: [www.cytopia.com.au](http://www.cytopia.com.au)